Eric Karas - Aug 19, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Aug 19, 2024
Transactions value $
-$125,000
Form type
4
Date filed
8/21/2024, 06:51 PM
Previous filing
Jan 4, 2024
Next filing
Sep 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $15K +10K +175.65% $1.50 15.7K Aug 19, 2024 Direct F1
transaction SPRY Common Stock Sale -$140K -10K -63.72% $14.00 5.69K Aug 19, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -10K -1.63% $0.00 605K Aug 19, 2024 Common Stock 10K $1.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
F3 Immediately exercisable.